News & Updates
Filter by Specialty:
Pamiparib works well against platinum-sensitive, -resistant ovarian cancer
The selective oral PARP1/2 inhibitor pamiparib is well tolerated and demonstrates favourable antitumour activity with durable responses in the treatment of patients with platinum-sensitive ovarian cancer or platinum-resistant ovarian cancer harbouring the germline BRCA mutation, according to the results of a phase II trial.
Pamiparib works well against platinum-sensitive, -resistant ovarian cancer
25 Feb 2022
Famotidine for mild-to-moderate COVID-19 succeeds in phase II trial
Use of famotidine in the treatment of outpatients with mild-to-moderate COVID-19 is safe and well tolerated, leading to rapid resolution of symptoms and inflammation without reducing anti-SARS-CoV-2 immunity, according to the results of a phase II trial.
Famotidine for mild-to-moderate COVID-19 succeeds in phase II trial
25 Feb 2022
Baricitinib keeps radiographic progression levels low in rheumatoid arthritis
Treatment with oral baricitinib steadily inhibits radiographic progression of structural joint damage in most patients with rheumatoid arthritis (RA), while achieving clinical improvement in disease activity, through 5 years as compared with initial conventional synthetic disease-modifying antirheumatic drug (csDMARD) or placebo, results of a study have shown.
